PHVS Pharvaris N.V.
USHealthcareAs of 2026-08-24
Why PHVS matters now
Pharvaris N.V. (PHVS) is a US stock in Healthcare. The latest InvestLog snapshot shows $37.31 with +2.87% on the session and $2.61B in market capitalization; recent performance reads 1-month +13.30% and YTD +18.20%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-39.8M, and EPS of $-0.61. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7.4%.
The latest indexable market news headline is "Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $52.00; recent insider activity includes Modig Berndt filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.90
P/S
0.00
EV/EBITDA
-10.50
DCF Value
$5.70
FCF Yield
-7.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-67.4%
ROA
-65.1%
ROIC
-72.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-39.8M | $-0.61 |
| Q4 2025 | $0.00 | $-46.7M | $-0.79 |
| FY 2025 | $0.00 | $-175.7M | $-2.97 |
| Q3 2025 | $0.00 | $-37.1M | $-0.60 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$56.00
Target (Median)
$52.00
Target Range
$42.00 - $74.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
NL
Exchange
—
Beta
-2.33
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and bringing to market treatments for uncommon diseases. Its primary pipeline asset, PHA121, is a small molecule bradykinin B2-receptor antagonist currently undergoing Phase II clinical trials for hereditary angioedema (HAE). Additionally, the company is advancing PHVS416, a swift-acting, on-demand soft capsule designed to alleviate acute HAE attacks, which is also in Phase 2 development. A third candidate, PHVS719, an extended-release prophylactic tablet aimed at preventing HAE episodes, is progressing through Phase 1 trials. Established in 2015 and headquartered in Leiden, the Netherlands, Pharvaris operates across the Netherlands, Switzerland, and the United States.